Literature DB >> 7540829

Synthetic peptides representing sequences within gp41 of HIV as immunogens for murine T- and B-cell responses.

L E Brown1, D O White, C Agius, B E Kemp, N Yatzakis, P Poumbourios, D A McPhee, D C Jackson.   

Abstract

Within the gp41 glycoprotein of the human immunodeficiency virus type 1 (HIV-1) there is a relatively conserved region which appears accessible to the immune system during the course of HIV infection and is recognised by antibody from virtually all patients with AIDS. This region has also been shown to function as a target for human T cells. We have examined synthetic peptides spanning this sequence, between residues 572 and 604, with a view to evaluating their potential as immunogens. Peptides 572GIKQLQARILAVERYLKDQQ591 and 579RILAVERYLKDQQLLGGIWGCSGK601 were good immunogens in two different strains of mice while peptide 576LQARILAVERYLKDQQ591 was an inferior immunogen, and peptide 593LGIWGCSGKLIC604 was non-immunogenic unless coupled to a carrier protein. For both antibody and T cell responses it was apparent that sequences that could function as determinants within one peptide could not do so in the context of a different peptide immunogen. It follows that by judicious choice of immunogen sequence it may be possible to direct the immune response towards a desired fine specificity. Unwanted responses by CD4+ T cells isolated from certain peptide-primed animals were also observed. These T cells showed an unusual reactivity in that they were incapable of recognising their determinant AVERYLKDQQ if it was extended at the C-terminal end with the native sequence and as such would not be expected to recognise the native molecule unless processing created the identical C-terminus.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7540829     DOI: 10.1007/bf01309955

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  48 in total

1.  A cluster of continuous antigenic structures in the transmembrane protein of HIV-1: individual patterns of reactivity in human sera.

Authors:  P J Klasse; R Pipkorn; J Blomberg
Journal:  Mol Immunol       Date:  1991-06       Impact factor: 4.407

2.  Class II-restricted T-cell clones to a synthetic peptide of influenza virus hemagglutinin differ in their fine specificities and in the ability to respond to virus.

Authors:  R A Ffrench; X L Tang; E M Anders; D C Jackson; D O White; H Drummer; J D Wade; G W Tregear; L E Brown
Journal:  J Virol       Date:  1989-07       Impact factor: 5.103

3.  Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160.

Authors:  P W Berman; T J Gregory; L Riddle; G R Nakamura; M A Champe; J P Porter; F M Wurm; R D Hershberg; E K Cobb; J W Eichberg
Journal:  Nature       Date:  1990-06-14       Impact factor: 49.962

4.  Hepatitis B synthetic immunogen comprised of nucleocapsid T-cell sites and an envelope B-cell epitope.

Authors:  D R Milich; J L Hughes; A McLachlan; G B Thornton; A Moriarty
Journal:  Proc Natl Acad Sci U S A       Date:  1988-03       Impact factor: 11.205

5.  Antibodies to an HIV-1 synthetic peptide with partial homology to MULV P15E do not protect against AIDS.

Authors:  J Lange; A Vahlne; J Dekker; F de Wolf; J Goudsmit
Journal:  AIDS       Date:  1989-06       Impact factor: 4.177

6.  Functional regions of the envelope glycoprotein of human immunodeficiency virus type 1.

Authors:  M Kowalski; J Potz; L Basiripour; T Dorfman; W C Goh; E Terwilliger; A Dayton; C Rosen; W Haseltine; J Sodroski
Journal:  Science       Date:  1987-09-11       Impact factor: 47.728

7.  Antibody to a synthetic oligopeptide in subjects at risk for human immunodeficiency virus infection.

Authors:  R S Smith; R B Naso; J Rosen; A Whalley; Y L Hom; K Hoey; C J Kennedy; J A McCutchan; S A Spector; D D Richman
Journal:  J Clin Microbiol       Date:  1987-08       Impact factor: 5.948

8.  A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition.

Authors:  C Wild; T Oas; C McDanal; D Bolognesi; T Matthews
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

9.  Human immunodeficiency virus neutralizing antibodies recognize several conserved domains on the envelope glycoproteins.

Authors:  D D Ho; M G Sarngadharan; M S Hirsch; R T Schooley; T R Rota; R C Kennedy; T C Chanh; V L Sato
Journal:  J Virol       Date:  1987-06       Impact factor: 5.103

10.  Diagnosis of AIDS by using a 12-amino acid peptide representing an immunodominant epitope of the human immunodeficiency virus.

Authors:  J W Gnann; P L Schwimmbeck; J A Nelson; A B Truax; M B Oldstone
Journal:  J Infect Dis       Date:  1987-08       Impact factor: 5.226

View more
  1 in total

1.  Identification of QS-21 as an Inflammasome-activating Molecular Component of Saponin Adjuvants.

Authors:  Robyn Marty-Roix; Gregory I Vladimer; Kimberly Pouliot; Dan Weng; Rachel Buglione-Corbett; Kim West; John D MacMicking; Jonathan D Chee; Shixia Wang; Shan Lu; Egil Lien
Journal:  J Biol Chem       Date:  2015-11-10       Impact factor: 5.157

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.